Noopur Raje, MD, on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

Video

The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

Access remains the most prevalent unmet need regarding CAR T-cell therapy, which is currently approved only for patients with late-stage relapsed or refractory multiple myeloma. Patients must wait and sometimes cannot receive the products in time.

OncLive spoke with Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusets General Hospital, about these unmet needs with CAR T-cell therapy in multiple myeloma. She discussed how improving access for these patients is a vital concern.

Raje discussed the potential of moving CAR T-cell therapy into earlier stages of treatment to help improve access and expand the number of patients who could receive treatment. Ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) are currently being investigated in the up-front setting in clinical trials. Once the indication is received in earlier stages of myeloma, bridging therapies will help more patients receive CAR T-cell therapy, Raje concluded.

Recent Videos
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.